Clinical trial
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With…
NCT00193089 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193089 |
|---|---|
| Title | Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer |
| Official title | Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients With Metastatic Breast Cancer and Overexpression of Her-2 |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Aventis Pharmaceuticals Industry GlaxoSmithKline |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Vinorelbine, Trastuzumab |
| Enrollment | 60 |
| Start date | Apr 1, 2001 |
| Primary completion | Apr 1, 2005 |
| Completion | Sep 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Dec 10, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: